Lake Street Advisors Group LLC Buys 341 Shares of Zoetis Inc. (NYSE:ZTS)

Lake Street Advisors Group LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 3.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,186 shares of the company’s stock after buying an additional 341 shares during the period. Lake Street Advisors Group LLC’s holdings in Zoetis were worth $1,823,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC lifted its position in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Zoetis during the third quarter worth approximately $31,000. First Personal Financial Services bought a new stake in shares of Zoetis during the third quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis in the third quarter valued at approximately $33,000. Finally, Dunhill Financial LLC lifted its holdings in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS stock opened at $164.99 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company’s 50 day moving average price is $166.22 and its two-hundred day moving average price is $177.58. The company has a market capitalization of $73.88 billion, a P/E ratio of 30.16, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. Zoetis’s dividend payout ratio is currently 36.56%.

Analysts Set New Price Targets

A number of research firms have commented on ZTS. Barclays lifted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. StockNews.com cut Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Sandler lowered their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Finally, Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $215.40.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.